Role of coagulation and fibrinolytic system in prostate cancer.
Patients with prostate carcinoma paradoxically have both a hypercoagulable state and a bleeding diathesis. Hypercoagulability manifested by venous and arterial thrombosis has been documented in several large clinical trials. However, many investigators have reported a high risk of postoperative bleeding in prostate cancer patients. Disseminated intravascular coagulopathy has also been commonly noted at different clinical stages of this indolent cancer. In this article we review clinical, laboratory, and experimental evidence for abnormalities of various components of the coagulation and plasminogen pathways and analyze their contribution in prostate cancer growth, progression, and angiogenesis. Finally, we propose potential therapeutic antiangiogenic strategies in patients with prostate cancer.
Kohli
Manish
M
Division of Hematology/Oncology, Department of Medicine, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas 72205, USA. Manish.Kohli@med.va.gov
Kaushal
Varsha
V
Mehta
Paulette
P
D001777:Blood Coagulation / Q000502:physiology*; D005342:Fibrinolysis; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009389:Neovascularization, Pathologic / Q000209:etiology; D011471:Prostatic Neoplasms / Q000097:blood* / Q000209:etiology / Q000473:pathology; D019851:Thrombophilia / Q000209:etiology